These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 31836549)

  • 1. Non-enhanced magnetic resonance imaging as a surveillance tool for hepatocellular carcinoma: Comparison with ultrasound.
    Park HJ; Jang HY; Kim SY; Lee SJ; Won HJ; Byun JH; Choi SH; Lee SS; An J; Lim YS
    J Hepatol; 2020 Apr; 72(4):718-724. PubMed ID: 31836549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma.
    Rimola J; Forner A; Sapena V; Llarch N; Darnell A; Díaz A; García-Criado A; Bianchi L; Vilana R; Díaz-González Á; Ayuso C; Bruix J; Reig M
    Eur Radiol; 2020 Jan; 30(1):186-194. PubMed ID: 31372783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of diagnostic performance of non-contrast MRI and abbreviated MRI using gadoxetic acid in initially diagnosed hepatocellular carcinoma patients: a simulation study of surveillance for hepatocellular carcinomas.
    Whang S; Choi MH; Choi JI; Youn SY; Kim DH; Rha SE
    Eur Radiol; 2020 Aug; 30(8):4150-4163. PubMed ID: 32166493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
    Zhang T; Huang ZX; Wei Y; Jiang HY; Chen J; Liu XJ; Cao LK; Duan T; He XP; Xia CC; Song B
    World J Gastroenterol; 2019 Feb; 25(5):622-631. PubMed ID: 30774276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of recurrent hepatocellular carcinoma after surgical resection: Non-contrast liver MR imaging with diffusion-weighted imaging versus gadoxetic acid-enhanced MR imaging.
    Min JH; Kim YK; Choi SY; Kang TW; Jeong WK; Kim K; Won HJ
    Br J Radiol; 2018 Oct; 91(1090):20180177. PubMed ID: 29927634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid.
    Besa C; Lewis S; Pandharipande PV; Chhatwal J; Kamath A; Cooper N; Knight-Greenfield A; Babb JS; Boffetta P; Padron N; Sirlin CB; Taouli B
    Abdom Radiol (NY); 2017 Jan; 42(1):179-190. PubMed ID: 27448609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gadoxetate-enhanced abbreviated MRI is highly accurate for hepatocellular carcinoma screening.
    Vietti Violi N; Lewis S; Liao J; Hulkower M; Hernandez-Meza G; Smith K; Babb JS; Chin X; Song J; Said D; Kihira S; Sirlin CB; Reeder SB; Bashir MR; Fowler KJ; Ferket BS; Sigel K; Taouli B
    Eur Radiol; 2020 Nov; 30(11):6003-6013. PubMed ID: 32588209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of biannual ultrasonography and annual non-contrast liver magnetic resonance imaging as surveillance tools for hepatocellular carcinoma in patients with liver cirrhosis (MAGNUS-HCC): a study protocol.
    Kim HA; Kim KA; Choi JI; Lee JM; Lee CH; Kang TW; Ku YM; Lee SL; Park YS; Yoon JH; Kim SH; Choi MH
    BMC Cancer; 2017 Dec; 17(1):877. PubMed ID: 29268722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of gadoxetic acid-enhanced MRI and diffusion-weighted imaging in the differentiation of hypervascular hyperplastic nodule from small (<3 cm) hypervascular hepatocellular carcinoma in patients with alcoholic liver cirrhosis: A retrospective case-control study.
    Kim SS; Kim SH; Song KD; Choi SY; Heo NH
    J Magn Reson Imaging; 2020 Jan; 51(1):70-80. PubMed ID: 31062483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterizing Computed Tomography-Detected Arterial Hyperenhancing-Only Lesions in Patients at Risk of Hepatocellular Carcinoma: Can Non-Contrast Magnetic Resonance Imaging Be Used for Sequential Imaging?
    Park SH; Kim B; Kim SY; Choi SJ; Huh J; Kim HJ; Kim KW; Lee SS
    Korean J Radiol; 2020 Mar; 21(3):280-289. PubMed ID: 32090520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease.
    Lee MH; Kim SH; Park MJ; Park CK; Rhim H
    AJR Am J Roentgenol; 2011 Nov; 197(5):W868-75. PubMed ID: 22021534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abbreviated MRI for Secondary Surveillance of Recurrent Hepatocellular Carcinoma After Presumed Curative Treatment.
    Jeon SK; Lee DH; Hur BY; Park SJ; Kim SW; Park J; Suh KS; Lee KW; Yi NJ; Han JK
    J Magn Reson Imaging; 2023 Nov; 58(5):1375-1383. PubMed ID: 36825827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of small hepatocellular carcinoma using gadoxetic acid-enhanced MRI: Is the addition of diffusion-weighted MRI at 3.0T beneficial?
    Zhao XT; Li WX; Chai WM; Chen KM
    J Dig Dis; 2014 Mar; 15(3):137-45. PubMed ID: 24354621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (<= 2.0 cm) in patients with hepatitis-induced liver cirrhosis.
    Park MJ; Kim YK; Lee MH; Lee JH
    Acta Radiol; 2013 Mar; 54(2):127-36. PubMed ID: 23148300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is 3-Tesla Gd-EOB-DTPA-enhanced MRI with diffusion-weighted imaging superior to 64-slice contrast-enhanced CT for the diagnosis of hepatocellular carcinoma?
    Maiwald B; Lobsien D; Kahn T; Stumpp P
    PLoS One; 2014; 9(11):e111935. PubMed ID: 25375778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocellular carcinoma with central scar on gadoxetic acid-enhanced and diffusion-weighted magnetic resonance imaging.
    Han SB; Kim YK; Min JH; Ha SY; Jeong WK; Lee WJ
    Acta Radiol; 2018 Apr; 59(4):393-401. PubMed ID: 28760004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of C-arm CT for transcatheter arterial chemoembolization of hepatocellular carcinoma: diagnostic performance and predictive value for therapeutic response compared with gadoxetic acid-enhanced MRI.
    Yu MH; Kim JH; Yoon JH; Kim HC; Chung JW; Han JK; Choi BI
    AJR Am J Roentgenol; 2013 Sep; 201(3):675-83. PubMed ID: 23971463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocellular carcinoma detection in liver cirrhosis: diagnostic performance of contrast-enhanced CT vs. MRI with extracellular contrast vs. gadoxetic acid.
    Semaan S; Vietti Violi N; Lewis S; Chatterji M; Song C; Besa C; Babb JS; Fiel MI; Schwartz M; Thung S; Sirlin CB; Taouli B
    Eur Radiol; 2020 Feb; 30(2):1020-1030. PubMed ID: 31673837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of non-contrast abbreviated MRI and ultrasound as surveillance modalities for HCC.
    Kim DH; Yoon JH; Choi MH; Lee CH; Kang TW; Kim HA; Ku YM; Lee JM; Kim SH; Kim KA; Lee SL; Choi JI
    J Hepatol; 2024 Sep; 81(3):461-470. PubMed ID: 38636849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic performance of gadoxetic acid-enhanced abbreviated magnetic resonance imaging protocol in small hepatocellular carcinoma (≤2 cm) in high-risk patients.
    Wang JH; Qiu QS; Dong SY; Chen XS; Wang WT; Yang YT; Sun W; Rao SX
    Acta Radiol; 2023 Oct; 64(10):2687-2696. PubMed ID: 37691270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.